// App-Quantinova.ai

2345 : SIRPFc, a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by both classically (M1) and alternatively (M2) activated macrophages

Researchers

Presenter

  • Gloria H. Y. Lin

Principal Investigators

  • Vien Chai

  • Vivian Lee

  • Karen Dodge

  • Tran Truong

  • Mark Wong

  • Lisa D. S. Johnson

  • Xinli Pang

  • Penka S. Petrova

  • Robert A. Uger

  • Natasja N. Viller

Medical Centers

  • Trillium Therapeutics Inc, Toronto, ON, Canada

Locations

  • Canada

Companies

  • Trillium Therapeutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved